Company Profile

Kintara Therapeutics is a biopharmaceutical company focused on the development and commercialization of new solid tumor cancer therapies.

REM-001 Therapy consists of three parts, a laser light source, a light delivery device and the drug REM-001 (collectively, REM-001 Therapy). REM-001 is a second generation photosensitizer drug that has undergone late stage clinical development, and which we believe possesses multiple advantages over earlier generation PDT compounds. Our lead indication for REM-001 Therapy is unresectable cutaneous metastatic breast cancer (CMBC), a disease that may affect individuals with advanced breast cancer and for which effective treatment options are limited. For this and similar cutaneous applications, the light delivery device is a simple and easy to use fiber optic wand that the physician employs to directly illuminate the tumor with light.

Latest Presentation

Industry Classifications

Sector:
Healthcare

Industry:
Pharmaceuticals

NAICS:
HMO Medical Centers (621491)

SIC:
Hospital And Medical Service Plans (6324)

Contact Information

Investor Relations
T: 858-350-4364
ir@kintara.com

Company Contact
Kintara Therapeutics, Inc.
9920 Pacific Heights Blvd, Suite 150
San Diego, CA 92121
United States
T: 858-350-4364
info@kintara.com